Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease

The N-methyl-d-aspartate receptor antagonist, memantine, is licensed for the treatment of moderate to severe Alzheimer’s disease (AD). Memantine is administered both as a monotherapy and as an add-on therapy in patients already receiving acetylcholinesterase inhibitors. Several meta-analyses have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Rive, Benoît, Gauthier, Serge, Costello, Sophie, Marre, Caroline, François, Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709077/
https://www.ncbi.nlm.nih.gov/pubmed/23765561
http://dx.doi.org/10.1007/s40263-013-0074-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709077/
https://www.ncbi.nlm.nih.gov/pubmed/23765561
http://dx.doi.org/10.1007/s40263-013-0074-x

Ejemplares similares